寶濟藥業(02659)注射用KJ103上市許可申請獲受理 X
04/06/2026 17:29
<匯港通訊>   寶濟藥業(02659)宣佈，由公司自主研發的注射用KJ103（研發代號KJ103）新藥上市許可申請(NDA)獲中國國家藥品監督管理局(NMPA)受理，用於高度致敏的腎移植患者進行脫敏治療，有效清除預存HLA抗體預防超急性排斥反應，並於2026年5月20日獲得NMPA藥品審評中心批准納入優先審評程序。 (WL)

(C) Copyright by Infocast Ltd. All Rights Reserved.

Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.